Mass spectrometry-based targeted proteomics supports each step of drug development, from early discovery to preclinical phases and even clinical phases. The webinar, entitled ‘MS-based targeted proteomics: A cornerstone to progress drug development through preclinical and clinical phases‘ is now available to watch on-demand. This webinar, hosted by DDW and… Read More
Mass spectrometry-based targeted proteomics supports each step of drug development, from early discovery to preclinical phases and even clinical phases. The webinar, entitled ‘MS-based targeted proteomics: A cornerstone to progress drug development through preclinical and clinical phases‘ is now available to watch on-demand. This webinar, hosted by DDW and… Read More
Mass spectrometry-based targeted proteomics supports each step of drug development, from early discovery to preclinical phases and even clinical phases. The webinar, entitled ‘MS-based targeted proteomics: A cornerstone to progress drug development through preclinical and clinical phases‘ is now available to watch on-demand. This webinar, hosted by DDW and… Read More
Mass spectrometry-based targeted proteomics supports each step of drug development, from early discovery to preclinical phases and even clinical phases. Registrations are now open for a new webinar taking place on 29 January 2026, entitled ‘MS-based targeted proteomics: A cornerstone to progress drug development through preclinical and clinical phases‘. Read More
Mass spectrometry-based targeted proteomics supports each step of drug development, from early discovery to preclinical phases and even clinical phases. Registrations are now open for a new webinar taking place on 29 January 2026, entitled ‘MS-based targeted proteomics: A cornerstone to progress drug development through preclinical and clinical phases‘. Read More
Mass spectrometry-based targeted proteomics supports each step of drug development, from early discovery to preclinical phases and even clinical phases. This webinar, hosted by DDW and supported by Evotec, will cover a diverse set of applications to illustrate how tailored and targeted proteomics fulfils scientific – and even regulatory –… Read More
Daniel Hornburg PhD, Vice-President Biomarkers & Precision Medicine, Bruker Daltonics, Stefan Foser, Vice President Global Pharma, Bruker Daltonics, and Torsten Müller, Business Development Manager, Proteomics, Bruker Daltonics, explore how MS-based proteomics can be used to dissect disease biology with spatial resolution. Impact of neurodegeneration for ageing societies… Read More
Kean Woodmansey, Senior Global Market Development Manager, Discovery (DMPK), SCIEX, examines how molecular precision is being enabled in GLP-1 therapies through the use of mass spectrometry. On Diabetes Alert Day in March, professionals across healthcare, research, and pharmaceutical development reflected on the pressing need for improved diabetes detection and treatment. Read More
Cerno will present new data on its universal mass spectrometry software at the American Society of Mass Spectrometry (ASMS) Annual Meeting in Baltimore MD. The Cerno team will also demonstrate their MassWorks and GC/ID software and meet with conference attendees at booth #121. “Across a… Read More
This is the latest episode of the free DDW narrated podcast, titled “New ways of looking at effective cancer treatment”, which covers three articles written for DDW Volume 24 – Issue 2, Spring 2023 of DDW. They are called: “3D Genomics and targeted cancer therapies”, “Democratising… Read More
This is the latest episode of the free DDW narrated podcast, titled “The far-reaching impact of drug discovery technology”, which covers three articles written for DDW Volume 24 – Issue 2, Spring 2023 of DDW. They are called: “Accelerating time to market through digitalisation”, “… Read More
DDW’s Diana Spencer examines the role of mass spectrometry in drug discovery and development. By measuring the mass-to-charge ratio of ions, mass spectrometry (MS) can identify unknown compounds, quantify known ones, and reveal the structure and chemical properties of molecules. It is highly sensitive and precise, making it an invaluable… Read More
The DDW Summer issue is out now and looks at where the global biotech hubs are for drug discovery and development, asks how 3D genomics can accelerate personalised medicine, and looks at the technological advances in mass spectrometry. It also includes an exclusive global cancer research guide examining the innovation happening… Read More
DDW’s Megan Thomas shines a spotlight on Rohan Thakur, President of Bruker Daltonics, as part of the first episode of the From the Top vodcast series. This interview took place while attending the opening of Bruker Corporation’s new production facility in Bremen. MT: What has you career path… Read More
Dr Sofia Ferreira, Director of Applications at Refeyn, discusses how various technologies can address the main challenges in membrane protein characterisation, describing how novel technologies, such as mass photometry, can streamline and support analytical processes. Dissecting the structure of membrane proteins Membrane proteins play a crucial role… Read More
Feeling isomer FOMO? Download this new whitepaper from MOBILion Systems ‘High-Throughput Monitoring of Biotherapeutic Critical Quality Attributes with High-Resolution Ion Mobility-Mass Spectrometry (HRIM-MS)’. MOBILion Systems is pioneering the evolution of separation science. High-resolution ion mobility (HRIM) on the MOBIE platform offers deeper, more accurate, and efficient characterisation of… Read More
